Mishima, Eikan http://orcid.org/0000-0002-3706-2745
Ito, Junya
Wu, Zijun http://orcid.org/0000-0002-5030-071X
Nakamura, Toshitaka
Wahida, Adam
Doll, Sebastian http://orcid.org/0000-0002-8933-5362
Tonnus, Wulf http://orcid.org/0000-0002-9728-1413
Nepachalovich, Palina http://orcid.org/0000-0002-3404-9537
Eggenhofer, Elke
Aldrovandi, Maceler
Henkelmann, Bernhard
Yamada, Ken-ichi http://orcid.org/0000-0003-2100-8477
Wanninger, Jonas
Zilka, Omkar http://orcid.org/0000-0003-3534-0470
Sato, Emiko
Feederle, Regina http://orcid.org/0000-0002-3981-367X
Hass, Daniela
Maida, Adriano
MourĂ£o, AndrĂ© Santos Dias
Linkermann, Andreas http://orcid.org/0000-0001-6287-9725
Geissler, Edward K. http://orcid.org/0000-0003-3661-6168
Nakagawa, Kiyotaka
Abe, Takaaki http://orcid.org/0000-0003-3170-4660
Fedorova, Maria
Proneth, Bettina http://orcid.org/0000-0002-4119-9437
Pratt, Derek A. http://orcid.org/0000-0002-7305-745X
Conrad, Marcus http://orcid.org/0000-0003-1140-5612
Article History
Received: 1 October 2021
Accepted: 23 June 2022
First Online: 3 August 2022
Competing interests
: M.C. and B.P. hold patents for some of the compounds described herein, and are co-founders and shareholders of ROSCUE Therapeutics GmbH. E.M. has filed a patent related to the treatment of ferroptosis-associated diseases with vitamin K. The other authors declare no competing interests.